Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...

If a company chooses to publish the data, it's usually once a year in their Annual Report. All data is manually compiled so there might be a delay between the Annual Report being published and the ...

Chimeric Therapeutics (ASX:CHM) has announced that the University of Chicago Medicine is now open to enrolling patients in the Phase 1/2 multi-centre ...

The ASX nudged up towards a record high this morning as traders breathed a sigh of relief over the latest tariff drama. The ...

Index rose 3.20% in January as markets had a strong start to 2025 with the benchmark S&P/ASX 200 rising by 5% to reach a new ...

Paul Hopper bought 200.00m shares over the last 12 months at an average price of AU$0.008. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on ...

If a company chooses to publish the data, it's usually once a year in their Annual Report. All data is manually compiled so there might be a delay between the Annual Report being published and the ...

Technology, electricity and data centre companies tumbled on the ASX on Tuesday, spooked by a sharp sell-off of Nvidia after Chinese start-up DeepSeek released its R1 artificial intelligence model.

The new and apparently lower-cost player from China saw America’s big tech stocks hammered on Wall Street overnight, which trickled down to local ASX-listed tech companies and real estate ...

Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies ...

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational ...